Treatment and prevention of intraepithelial neoplasia: An important target for accelerated new agent development: Recommendations of the American association for cancer research Task force on the Treatment and Prevention of intraepithelial neoplasia

Clinical Cancer Research

Volumn 8, Issue 2, 2002, Pages 314-346

  O’Shaughnessy, Joyce A ^a   Kelloff, Gary J ^b   Gordon, Gary B ^c   Dannenberg, Andrew J ^d   Hong, Waun Ki ^e   Fabian, Carol J ^f   Sigman, Caroline C ^g   Bertagnolli, Monica M ^h   Stratton, Steven P ⁱ   Lam, Stephen ^j   Nelson, William G ^k   Meyskens, Frank L ^l   Alberts, David S ⁱ   Follen, Michele ^e   Rustgi, Anil K ^m   Papadimitrakopoulou, Vali ^e   Scardino, Peter T ⁿ   Gazdar, Adi F ^o   Wattenberg, Lee W ^p   Sporn, Michael B ^q   Sakr, Wael A ^r   Lippman, Scott M ^e   Von Hoff, Daniel D ⁱ   more..

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c LUNDBECK RESEARCH USA   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^g CCS Associates   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ UNIVERSITY OF ARIZONA   (United States)

^j British Columbia Cancer Research Centre   (United States)

^k JOHNS HOPKINS UNIVERSITY   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY OF PENNSYLVANIA   (United States)

ⁿ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^o UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^p UNIVERSITY OF MINNESOTA   (United States)

^q DARTMOUTH MEDICAL SCHOOL   (United States)

^r WAYNE STATE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA TOCOPHEROL; BETA CAROTENE; RETINOIC ACID;

ARTICLE; CANCER INVASION; CANCER RISK; CARCINOGENESIS; DISEASE MARKER; DRUG TARGETING; GENE MUTATION; GENETIC PREDISPOSITION; HIGH RISK PATIENT; HUMAN; INCIDENCE; INTRAEPITHELIAL NEOPLASIA; MORBIDITY; NONHUMAN; PATIENT MONITORING; PRECANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BARRETT ESOPHAGUS; CARCINOMA IN SITU; CARDIOVASCULAR DISEASES; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLINICAL TRIALS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; KERATOSIS; MALE; MOUTH NEOPLASMS; NEOPLASMS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 0036184605     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (329)

1. Prevention of cancer in the next millennium: Report of the Chemoprevention Working Group to the American Association for Cancer Research
2. Recent advances in chemoprevention of cancer
3. Perspectives on cancer chemoprevention research and drug development
4. Cancer chemoprevention: Progress and promise
5. Cancer chemoprevention: Progress promise
6. Approaches to the development and marketing approval of drugs that prevent cancer
7. Perspectives on surrogate endpoints in the development of drugs that reduce the risk of cancer
8. In situ breast carcinoma
9. Atypical hyperplastic lesions of the female breast. A long-term follow-up study
10. A multicenter study of colorectal adenomas. Rationale, objectives, methods and characteristics of the study cohort
11. The adenoma-carcinoma sequence
12. The adenoma-adenocarcinoma sequence in the large bowel: Variations on a theme
13. Pathology and biology of colorectal neoplasia
14. Prostatic intraepithelial neoplasia (PIN): Current concepts
15. The evolution of cancer of the colon and rectum
16. Prostatic intra-epithelial neoplasia and early invasion in prostate cancer
17. Prostatic intraepithelial neoplasia: A premalignant lesion
18. Prostatic intraepithelial neoplasia: Significance and management
19. High grade prostatic intraepithelial neoplasia: The most likely precursor of prostate cancer
20. Epidemiology of high-grade prostatic intraepithelial neoplasia
21. Cellular and molecular pathology of prostate cancer precursors
22. Clinical management of familial adenomatous polyposis
23. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
24. Cancers of the gastrointestinal tract: Cancer of the esophagus
25. Cancers of the genitourinary system
26. Chemoprevention strategies for lung and upper aerodigestive tract cancer
27. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma
28. Adenocarcinoma arising in Barrett's esophagus
29. "Field cancerization" in oral stratified squamous epithelium. Clinical implications of multicentric origin
30. Surrogate endpoints in clinical trials: Are we being misled?
31. A regulatory authority's opinion about surrogate endpoints
32. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II)
33. Prevention of restenosis by lovastatin after successful coronary angioplasty
34. The long-term clinical efficacy of lovastatin therapy following successful coronary angioplasty
35. Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I)
36. Pravastatin, lipids, and atherosclerosis in the carotid arteries: Design features of a clinical trial with carotid atherosclerosis outcome
37. Helsinki Heart study. Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
38. Cholesterol reduction yields clinical benefit. A new look at old data
39. Coronary heart disease, hypercholesterolemia, and atherosclerosis. II. Misrepresented data
40. Cancer statistics, 2001
41. Prevention of colorectal cancer by colonoscopic polypectomy
42. Proctosigmoidoscopy and polypectomy in reducing the incidence of rectal cancer
43. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas
44. Lessons from hereditary colorectal cancer
45. Genetic pathways in colorectal and other cancers
46. Natural history of aberrant crypt foci. A surgical approach
47. K-ras mutations in putative preneoplastic lesions in human colon
48. Aberrant crypt foci of the colon as precursors of adenoma and cancer
49. A genetic model for colorectal tumorigenesis
50. Risk of colorectal cancer in adenoma-bearing individuals within a defined population
51. Hormones colon cancer
52. A meta-analysis of hormone replacement therapy and colon cancer in women
53. Polyps as biomarkers for colorectal neoplasia
54. The National Polyp study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas
55. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps
56. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer
57. Effect of fecal occult blood testing on mortality from colorectal cancer. A case-control study
58. Screening sigmoidoscopy and colorectal cancer mortality
59. Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans
60. Common inheritance of susceptibility to colonic adenomatous polyps and associated colorectal cancers
61. The evolution of colorectal carcinoma
62. Premalignancy of the mucosal polyp in the large intestine. II. Estimation of the periods required for malignant transformation of mucosal polyps
63. Risk of colorectal cancer in the families of patients with adenomatous polyps
64. Aspirin use and reduced risk of fatal colon cancer
65. Aspirin and the risk of colorectal cancer in women
66. Nonsteroidal antiinflammatory drugs and colorectal cancer
67. Reduced risk of large-bowel adenomas among aspirin users
68. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: Case-control study of subjects participating in the Nottingham faecal occult blood screening programme
69. Aspirin and other nonsteroidal anti-inflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals
70. Low-dose aspirin and incidence of colorectal tumors in a randomized trial
71. Family history, metabolic gene polymorphism, diet and risk of colorectal cancer
72. Distal colonic neoplasms predict proximal neoplasia in average-risk, asymptomatic subjects
73. Biomarkers of increased susceptibility to gastrointestinal cancer: New application to studies of cancer prevention in human subjects
74. Inhibition of apoptosis during development of colorectal cancer
75. Aberrant crypt foci in colorectal carcinogenesis. Cell and crypt dynamics
76. Sulindac causes regression of rectal polyps in familial adenomatous polyposis
77. Spontaneous resolution of rectal polyps in patients with familial polyposis following abdominal colectomy and ileorectal anastomosis
78. Effect of wheat fiber and vitamins C and E on rectal polyps in patients with familial adenomatous polyposis
79. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
80. Colon cancer: A review of the epidemiology
81. Identification of FAP locus genes from chromosome 5q21
82. Identification and characterization of the familial adenomatous polyposis coli gene
83. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC
84. Hereditary nonpolyposis colorectal cancer
85. Cancer risk associated with germline DNA mismatch repair gene mutations
86. Population-based surveillance by colonoscopy: Effect on the incidence of colorectal cancer. Telemark Polyp study I
87. Cancer statistics, 2000
88. Head neck cancer
89. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients
90. Long term follow-up study of laryngeal precancer
91. High frequency of p16 (CDKN2/MTS-I/INK4A) inactivation in head and neck squamous cell carcinoma
92. Frequent inactivation of p16INK4a in oral premalignant lesions
93. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment
94. Accumulation of p53 protein and retinoic acid receptor β in retinoid chemoprevention
95. Dysregulated cyclin D1 expression early in head and neck tumorigenesis: In vivo evidence for an association with subsequent gene amplification
96. Asynchronous modulation of transforming growth factor α and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma
97. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis
98. Suppression of retinoic acid receptor-β in premalignant oral lesions and its up-regulation by isotretinoin
99. Cancer chemoprevention
100. 13-cis-Retinoic acid in the treatment of oral leukoplakia
101. Comparison of low-dose isotretinoin with β-carotene to prevent oral carcinogenesis
102. Low-dose isotretinoin versus β-carotene to prevent oral carcinogenesis: Long-term follow-up
103. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract
104. The changing epidemiology of esophageal cancer
105. Endoscopy of the upper gastrointestinal tract
106. Etiology of Barrett's metaplasia and esophageal adenocarcinoma
107. Adenocarcinoma of the esophagus and Barrett's esophagus: A population-based study
108. Reflux disease and Barrett's esophagus
109. Reflux disease and Barrett's esophagus
110. Barrett's esophagus: Age, prevalence, and extent of columnar epithelium
111. Epidemiology of columnar-lined esophagus and adenocarcinoma
112. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus
113. Adenocarcinoma of the esophagogastric junction and Barrett's esophagus
114. Barrett's esophagus. Natural history, incidence, etiology, and complications
115. Biology of Barrett's esophagus and adenocarcinoma
116. The molecular basis for carcinogenesis in metaplastic columnar-lined esophagus
117. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: Prospective endoscopic surveillance of a cohort
118. Biomarkers for malignancy in the columnar-lined esophagus
119. Reduction to homozygosity involving p53 in esophageal cancers demonstrated by the polymerase chain reaction
120. 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy
121. Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma
122. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue
123. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma
124. Photodynamic therapy for Barrett's esophagus: Clinical update
125. Estimates of the worldwide incidence of 25 major cancers in 1990
126. The Bethesda system for reporting cervical/vaginal cytological diagnoses
127. Interim guidelines for management of abnormal cervical cytology
128. Cervical neoplasia and other STD-related genital and anal neoplasias
129. Abnormal cervical smears in the military recruit population
130. Results from the national breast and cervical cancer early detection program, October 31-September 30, 1993
131. Fatti statici relativialle malatia cancerose
132. Risk factors for cervical neoplasia in Denmark
133. Cervical cancer and human papillomavirus: Epidemiological evidence and perspectives for prevention
134. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia
135. Epidemiology of genital human papillomavirus infection
136. Natural history of cervical intraepithelial neoplasia: A critical review
137. Cervical human papillomavirus infection and intraepithelial neoplasia: A review
138. A follow-up study of patients with cervical dysplasia
139. Genetic alterations accumulate during cervical tumorigenesis and indicate a common origin for multifocal lesions
140. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: A randomized trial
141. The natural history of cervical intraepithelial neoplasia: An argument for intermediate endpoint biomarkers
142. Chemoprevention of cervical cancer with folic acid: A Phase III Southwest Oncology Group Intergroup study
143. Oral folic acid supplementation for cervical dysplasia: A clinical intervention trial
144. β-Carotene treatment of cervical intraepithelial neoplasia: A Phase II study
145. Randomized double-blind trial of β-carotene and vitamin C in women with minor cervical abnormalities
146. Chemoprevention trials and surrogate endpoint biomarkers in the cervix
147. Natural history of cervical squamous intraepithelial lesions: A meta-analysis
148. Patterns of absolute risk of lung cancer mortality in former smokers
149. Cytological studies in man and animals on development of bronchogenic carcinoma
150. Carcinoma in situ of the lung: Its development, detection, and treatment
151. Development of carcinoma of the lung as reflected in exfoliated cells
152. Histologic findings in the tracheobronchial tree of uranium miners and non-miners with lung cancer
153. Changes in bronchial epithelium in relation to cigarette smoking and in relation to lung cancer
154. Diagnostic significance of "severe dysplasia" in sputum cytology
155. Sputum cytopathology: Use and potential in monitoring the workplace environment by screening for biological effects of exposure
156. Metaplasia and atypical metaplasia in the bronchial epithelium: A histopathologic and cytopathologic study
157. Reversibility of bronchial marked atypia: Implication for chemoprevention
158. Pathogenesis of epidermoid carcinoma of lung
159. Cytopathological analysis of sputum in patients with airflow obstruction and significant smoking histories
160. Sex-related differences in bronchial epithelial changes associated with tobacco smoking
161. Detection and localization of early lung cancer by fluorescence bronchoscopy
162. Bronchioloalveolar cell adenomas
163. Adenomatous hyperplasia and the origin of peripheral adenocarcinoma of the lung
164. Atypical adenomatous hyperplasia of the lung and its differentiation from adenocarcinoma. Characterization of atypical cells by morphometry and multivariate cluster analysis
165. Small peripheral glandular lesions detected by screening CT for lung cancer. A diagnostic dilemma for the pathologist
166. Comparative ultrastructural study of atypical adenomatous hyperplasia and adenocarcinoma of the human lung
167. Atypical adenomatous hyperplasia of the lung. Implications for the pathogenesis of peripheral lung adenocarcinoma
168. Molecular changes in the bronchial epithelium of patients with small cell lung cancer
169. Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer
170. Clonal genetic alterations in the lungs of current and former smokers
171. Molecular damage in the bronchial epithelium of current and former smokers
172. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma
173. Allelic losses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer
174. Molecular abnormalities in the sequential development of lung carcinoma
175. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints
176. Diagnostic results before and after introduction of autofluorescence bronchoscopy in patients suspected of having lung cancer detected by sputum cytology in lung cancer mass screening
177. A follow-up study of squamous dysplasia
178. A prospective, short term follow-up study of 59 severe dysplasias and carcinoma in situ of the bronchus using auto fluorescence endoscopy
179. Outcome of bronchial carcinoma in situ
180. Roentgenographically occult lung cancer. A ten-year experience
181. Results of surgical treatment for roentgenographically occult bronchogenic squamous cell carcinoma
182. Photodynamic therapy of lung cancer
183. Nd:YAG laser therapy in lung cancer: An 11 year experience with 2,253 applications in 1,585 patients
184. Radiographically occult lung cancer treated with fiberoptic bronchoscopic electrocautery: A pilot study of a simple and inexpensive technique
185. Cryotherapy of in-situ or microinvasive bronchial carcinoma
186. Curative endobronchial therapy in early-stage non-small cell lung cancer
187. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck
188. Adjuvant treatment of stage I lung cancer with high-dose vitamin A
189. Endoscopic localization of preneoplastic lung lesions
190. Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy
191. Properties of intraepithelial neoplasia relevant to the development of cancer chemopreventive agents
192. Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice
193. Studies of chemopreventive effects of budenoside on benzo[a]pyrene-induced neoplasia of the lung of female A/J mice
194. Cancer statistics, 1997
195. Epidemiology of cancers of the skin
196. Basal cell carcinoma
197. High-risk nonmelanoma skin cancers
198. Epidemiology of actinic keratoses and squamous cell carcinoma
199. Observations respecting an ulcer of peculiar character, which attacks the eyelids and other parts of the face
200. Nonmelanoma skin cancer mortality in the United States, 1969 through 1988
201. Sun exposure, skin cancers and related skin conditions
202. Epidemiology of nonmelanoma skin cancer
203. Effect of age on the formation and repair of UV photoproducts in human skin in situ
204. An overview of skin cancers. Incidence and causation
205. The incidence of tumours in renal transplant recipients with long-term immunosuppressive therapy
206. Awareness of skin cancer by kidney transplant patients
207. Skin cancer in liver transplant recipients
208. Skin cancer in heart transplant recipients: Frequency and risk factor analysis
209. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens
210. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens
211. Incidence of skin cancer in 5356 patients following organ transplantation
212. Posttransplantation skin cancer: Scope of the problem, management, and role for systemic retinoid chemoprevention
213. Cyclosporine induces cancer progression by a cell-autonomous mechanism
214. The state-of-the-art in chemoprevention of skin cancer
215. Clinical presentation of actinic keratoses and squamous cell carcinoma
216. Histopathology of incipient intraepidermal squamous cell carcinoma ("actinic keratosis")
217. Metastatic cutaneous squamous cell carcinoma derived from actinic keratosis
218. Incipient intraepidermal cutaneous squamous cell carcinoma: A proposal for reclassifying and grading solar (actinic) keratoses
219. Characteristics of office-based visits for skin cancer. Dermatologists have more experience than other physicians in managing malignant and premalignant skin conditions
220. Skin conditions and related need for medical care among persons 1-74 years. United States, 1971-1974
221. Frequency of skin cancer and solar keratoses in a rural southern county as determined by population sampling
222. Association of nonmelanoma skin cancer and actinic keratosis with cumulative solar ultraviolet exposure in Maryland watermen
223. Epidemiology of solar keratoses
224. The treatment of actinic keratoses
225. The pathogenesis of squamous cell cancer: Lessons learned from studies of skin carcinogenesis
226. Skin cancer solar UV radiation
227. Spontaneous remission of solar keratoses: The case for conservative management
228. Malignant transformation of solar keratoses to squamous cell carcinoma
229. The relationship of basal cell carcinomas and squamous cell carcinomas to solar keratoses
230. Precursors to skin cancer
231. The incidence of non-melanocytic skin cancers in an Australian population: Results of a five-year prospective study
232. Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspective
233. Design and recruitment for retinoid skin cancer prevention (SKICAP) trials
234. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: A randomized, double-blind, controlled trial
235. Anatomic markers of human premalignancy and risk of breast cancer
236. Mammary intraepithelial neoplasia: A translational classification system for the intraductal epithelial proliferations
237. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia
238. Overview of the biology and management of ductal carcinoma in situ of the breast
239. Lobular carcinoma in situ of the breast
240. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17
241. Ultrasound-guided fine-needle aspiration (FNA) of nonpalpable breast lesions: A review of 1885 FNA cases using the National Cancer Institute-supported recommendations on the uniform approach to breast FNA
242. Histologic correlation of image-guided core biopsy with excisional biopsy of nonpalpable breast lesions
243. Association of breast cancer with the finding of atypical ductal hyperplasia at core breast biopsy
244. Breast cancer and atypia among young and middle-aged women: A study of 110 medicolegal autopsies
245. Alterations in DNA methylation: A fundamental aspect of neoplasia
246. Loss of p16INK4 expression by methylation is associated with life span extension of human mammary epithelial cells
247. Methylation and silencing of the retinoic acid receptor-β2 gene in breast cancer
248. Aberrant methylation of the estrogen receptor and E-cadherin 5′ CpG islands increases with malignant progression in human breast cancer
249. Transforming growth factor-β and breast cancer risk in women with mammary epithelial hyperplasia
250. Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors
251. Estrogen receptor expression in benign breast epithelium and breast cancer risk
252. Expression of the c-erbB-2 proto-oncogene product and nuclear DNA content in benign and malignant human breast parenchyma
253. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
254. Differential expression of estrogen, progesterone, and epidermal growth factor receptors in normal, benign, and malignant human breast tissues using dual staining immunohistochemistry
255. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas
256. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer
257. Expression of proliferation and apoptosis-related proteins in usual ductal hyperplasia of the breast
258. Reduction in apoptosis relative to mitosis in histologically normal epithelium accompanies fibrocystic change and carcinoma of the premenopausal human breast
259. Cellular oxidative stress and the control of apoptosis by wild-type p53, cytotoxic compounds, and cytokines
260. p53 protein expression and nuclear DNA content in breast intraductal proliferations
261. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization
262. Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk
263. p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias
264. Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model
265. Chromosomal aneuploidy in proliferative breast disease
266. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci
267. Loss of heterozygosity at chromosome 6q in preinvasive and early invasive breast carcinomas
268. Numerical abnormalities of chromosomes 7, 18, and X in precancerous breast disease defined by fluorescent in situ hybridization
269. Atypia in breast fine-needle aspiration smears correlates poorly with the presence of a prognostically significant proliferative lesion of ductal epithelium
270. Interobserver variability in the classification of proliferative breast lesions by fine-needle aspiration: Results of the Papanicolaou Society of Cytopathology study
271. Can nonproliferative breast disease and proliferative breast disease without atypia be distinguished by fine-needle aspiration cytology?
272. Borderline epithelial lesions of the breast
273. Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria
274. Consensus Conference on the classification of ductal carcinoma in situ
275. Consistency achieved by 23 European pathologists in categorizing ductal carcinoma in situ of the breast using five classifications
276. The uniform approach to breast fine-needle aspiration biopsy
277. Prospective evaluation of radiologically directed fine-needle aspiration biopsy of nonpalpable breast lesions
278. Image morphometric nuclear grading of intraepithelial neoplastic lesions with applications to cancer chemoprevention trials
279. Cytologic identification of clinically occult proliferative breast disease in women with a family history of breast cancer
280. Breast cancer risk associated with abnormal cytology in nipple aspirates of breast fluid and prior history of breast biopsy
281. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
282. Identification of premalignant and malignant breast cells in mammogram- and physical-exam negative women by ductal lavage
283. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer
284. Epidemiology of prostate cancer chemoprevention
285. Introductory remarks: Development of chemopreventive agents for prostate cancer
286. Prostatic intraepithelial neoplasia: A marker for high-risk groups and a potential target for chemoprevention
287. Prostate cancer
288. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia
289. CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: A new prostate cancer biomarker
290. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization
291. Androgen-independent prostate cancer progression in the TRAMP model
292. Chemoprevention of prostate carcinogenesis by α-difluoromethylornithine in TRAMP mice
293. Chemoprevention of prostate cancer: Concepts and strategies
294. Chemoprevention of prostate cancer: Guidelines for possible intervention strategies
295. Cancer of the bladder
296. Epidemiology of bladder cancer
297. The lower urinary tract: Urinary bladder: Neoplasms
298. Natural history of superficial bladder cancer. Prognostic features and long-term disease course
299. The T1 bladder tumor
300. Bladder cancer - Field versus clonal origin
301. Treatment of superficial bladder tumors: Achievements and needs
302. Molecular genetics and biochemical mechanisms in bladder cancer. Oncogenes, tumor suppressor genes, and growth factors
303. Molecular detection of primary bladder cancer by microsatellite analysis
304. Use of markers in defining urothelial premalignant and malignant conditions
305. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates
306. Expression of immunohistochemical markers (PCNA, Ki-67, 486p and p53) on paraffin sections and their relation to the recurrence rate of superficial bladder tumors
307. Detection of autocrine motility factor in urine as a marker of bladder cancer
308. Intervention strategies for chemoprevention of bladder cancer
309. Chemoprevention of bladder and prostate carcinoma
310. Retinoids in the chemoprevention of bladder cancer
311. Chemoprevention of urological cancer
312. Non-steroidal anti-inflammatory drugs and bladder cancer prevention
313. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: Prevalence and clinical data
314. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia
315. Predicting cancer development in oral leukoplakia: Ten years of translational research
316. Barrett's esophagus. Prevalence and incidence of adenocarcinoma
317. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus
318. Increased expression of epidermal growth factor receptors in Barrett's esophagus associated with alkaline reflux: A putative model for carcinogenesis
319. The CIN saga - The biological and clinical significance of cervical intraepithelial neoplasia
320. Rational targets for the early detection of lung cancer
321. Squamous metaplasia of the bronchial mucosa and its relationship to smoking
322. p53 and ras gene mutations in lung cancer: Implications for smoking and occupational exposures
323. Relationship of solar keratosis and history of skin cancer to objective measures of actinic skin damage
324. High incidence and regression rates of solar keratoses in a Queensland community